Apimeds Pharmaceuticals US, Inc. (APUS) Stock Price & Analysis
Apimeds Pharmaceuticals US, Inc. (APUS) closed at USD 4.39 on Thursday, October 15, 2026, down 4.15% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.39; the Oct 15, 2026 session ranged USD 4.01–4.42 on volume of 108,985 shares. Market capitalization is —, with a 52-week range of USD 1.51–59.7 (ASE). Source: Nexqual, retrieved October 16, 2026 at 05:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/APUS.md
Key facts (APUS)
- Total return with dividends: 1Y -76.1% vs S&P 500 +18.1%; 5Y -80.0% vs S&P 500 +85.1%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (APUS)
| USD | FY2024 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Operating income | -$747K | -$1.3M | -$11.9M | -$27.3M |
| Net income | -$778K | -$1.4M | -$6.0M | -$58.2M |
| EPS (diluted) | -$1.70 | -$1.80 | -$5.50 | — |
| Free cash flow | — | — | -$9.0M | -$13.3M |
| Cash + short-term investments | $410K | $3K | $3.6M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (APUS)
Total return (dividends reinvested) (APUS)
| 1Y (from 2025-10-16) | 5Y (from 2025-05-05) | |
|---|---|---|
| Total return | -76.1% | -80.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -76.3% | -67.2% |
| Volatility (annualized) | 190.6% | 179.6% |
| Max drawdown | -95.9% (Nov 2025→Sep 2026) | -94.5% (Nov 2025→Sep 2026) |
Key Statistics (as of October 16, 2026 at 05:49 UTC)
| Price | USD 4.39 |
|---|---|
| Change | ▼ 4.15% (down) |
| Previous Close | USD 4.39 |
| Open | USD 4.39 |
| Day Range | USD 4.01 – 4.42 |
| 52-Week Range | USD 1.51 – 59.7 |
| Volume | 108,985 shares |
| Market Cap | — |
| Exchange | ASE |
Technical Analysis (APUS)
Nexqual's technical model rates APUS "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of October 16, 2026 at 05:49 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.67 (neutral) |
| vs SMA50 | Above (USD 3.97) |
| MACD | 0.34 (positive) |
Earnings (APUS)
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Financials & Fundamentals (APUS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Ownership (APUS)
| Insider Ownership | +58.70% |
|---|---|
| Institutional Ownership | +2.83% |
| Shares Outstanding | 1.51M |
| Short % of Float | +9.87% |
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 39.57 | ▼ 5.81% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt